Skip to main content

Search

Reset all filters
136 Result(s)
Sort by

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis 

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis 

Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer
Parasiticides

Parasiticides

Science and Innovation - Animal Health Innovation - Parasiticides
INSPIRED

INSPIRED

Read more about INSPIRED, aimed at expanding a hospital-to-home program to better support people living with chronic obstructive pulmonary disease (COPD).
ABILD02

ABILD02

The ABILD02 partnership aims to understand ILD patients needing oxygen therapy, identifying facilitators and barriers to its use via stakeholder consultations.
Ensho Health

Ensho Health

Boehringer Ingelheim Canada, community cardiologists, and Ensho Health collaborated to create a tool optimizing care for chronic conditions in Alberta. More info.
Machine learning for patients

Machine learning for patients

Using AI to power patient-centric guideline optimization: discover the collaboration between Boehringer Ingelheim Canada, a community of cardiologists and Ensho Health.
Medly Program

Medly Program

Learn more about the Medly Program and the partnership between Toronto’s UHN and Boehringer Ingelheim Canada to expand it to additional communities.